ESR2 and ovarian carcinoma: Further support is provided by ERβ-specific agonists, e.g., 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN), inhibiting the growth of ovarian carcinoma cells [37,41,42,43] and ERβ-specific antagonists, e.g., 4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo [1,5-a]-pyrimidin-3-yl]phenol (PHTPP), enhancing growth [37].